Marius Müller

Marius Müller serves as a Guest Researcher in the Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences at the University of Copenhagen. His work centers on advancing radiopharmaceutical sciences through innovative approaches to targeted therapy and molecular imaging.

His research spans medicinal chemistry, radiochemistry, and nuclear medicine with emphasis on tetrazine-based bioorthogonal systems, radionuclide labeling techniques (particularly astatine-211, carbon-11, and fluorine-18), and pretargeted strategies for cancer therapy. Key interests include optimizing in vivo stability of radiolabeled compounds, developing novel synthetic methodologies for PET tracer production, and evaluating pharmacokinetic properties of imaging agents.

Analysis of his 2024-2025 publications reveals a strong focus on improving pretargeted radiotherapeutic efficacy through tetrazine chemistry innovations, with significant contributions to astatine-211 radiopharmaceutical development and carbon-11 labeling techniques. His work consistently addresses critical challenges in radionuclide stability and targeting precision across multiple therapeutic and diagnostic applications.